SciFocus/Press Release/Mumbai, India – Global pharmaceutical leader Lupin Limited has expanded its diabetes care offerings with the acquisition of Huminsulin® from Eli Lilly and Company in India. The acquisition aligns with Lupin’s strategy to enhance its position in the diabetes management market by providing a comprehensive suite of human insulin products.
Huminsulin products, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, are critical for managing blood sugar levels in both type 1 and type 2 diabetes patients.
Executive Insights
- Nilesh Gupta, Managing Director of Lupin:
“This acquisition underscores our commitment to delivering high-quality and affordable diabetes care solutions, complementing our existing portfolio and catering to a growing patient base.”
- Rajeev Sibal, President – India Region Formulations:
“With this acquisition, Lupin solidifies its leadership in the diabetes segment, empowering healthcare providers with more therapeutic options.”
Key Industry Impact
- Strengthened Portfolio: Adds a proven range of human insulin therapies to Lupin’s product offerings.
- Market Growth Potential: Addresses the increasing demand for effective diabetes management solutions in India, home to one of the largest diabetic populations globally.
- Collaborative Success: Leverages Lupin’s established distribution network to optimize accessibility and delivery.
Lupin’s acquisition is poised to set new standards in diabetes care by ensuring innovation, affordability, and accessibility.
About Lupin
A global leader in pharmaceuticals, Lupin excels in branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Its strong global presence and innovative pipeline make it a trusted partner in healthcare.
Visit www.lupin.com for more details.
Source: https://www.lupin.com/lupin-acquires-huminsulin-from-lilly-to-enhance-diabetes-portfolio/
